title: Radionuclide Therapy for Neuroendocrine Tumors.
abstract: Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT,90Y-DOTATOC and177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared177Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.
authors.affiliation: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
authors.forename: Mauro
authors.initials: M
authors.lastname: Cives
authors.affiliation: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. jonathan.strosberg@moffitt.org.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Strosberg
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008168:Lung / Q000473:pathology / Q000528:radiation effects; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010179:Pancreas / Q000473:pathology / Q000528:radiation effects; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000528:radiation effects; D013270:Stomach / Q000473:pathology / Q000528:radiation effects
chemical_list: D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C496730:90Y-octreotide, DOTA-Tyr(3)-; C447941:lutetium Lu 177 dotatate; D015282:Octreotide
keywords: Carcinoid tumors; Lutetium; NETTER-1; PRRT; Radiolabeled somatostatin analogs